Business
Guardant Health Presents New Data Showing Blood Test Highly Accurate in Detecting Multiple Cancers at the American Association for Cancer Research Annual Meeting
- Multi-Cancer Assay Highly Sensitive and Specific in Screening for Detection of Early-Stage Cancers, Able to Identify Tumor Tissue of Origin with High
About this update from Guardant Health, Inc.
[{"type":"text","content":"\n- Multi-Cancer Assay Highly Sensitive and Specific in Screening for Detection of Early-Stage Cancers, Able to Identify Tumor Tissue of Origin with High Accuracy\n\n REDWOOD CITY, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new data demonstrating the ability of the company’s investigational next-generation Guardant SHIELD™ multi-cancer assay to accurately detect early-stage cancers. This assay is designed to analyze approximately 20,000 epigenomic biomarkers that are informative for detection of a wide range of solid tumors in a single blood test. The data for four cancer types were demonstrated as examples: colorectal, lung, pancreatic and bladder. These cancers alone account for more than 200,000 cancer-related deaths in the U.S. annually.1 In addition, the blood test identified the tumor tissue of origin with high accuracy. These data were presented during an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting.\n\nData from the presentation show that the next-generation Guardant SHIELD multi-cancer screening assay achieved sensitivity (detection rates) of 90% (n=692) in stages I and II colorectal cancer (CRC) and 87% (n=55) in stages I and II lung cancer. For more advanced cancer (stages III and IV), sensitivity was 93% (n=582) for CRC and 93% (n=136) for lung cancer. Detection was assessed at 90% specificity (true negative rates) based on a cohort of patients without cancer. This performance is on par with current guideline-recommended screening methods. Current screening options for these cancers, while effective, are limited due to low compliance rates: 66% for CRC and 14% for lung cancer.2,3 A high-performance blood test that can be completed as part of a routine patient workup has the potential to improve screening rates and, ultimately, save more lives.\n\nIn addition, the multi-cancer screening assay achieved sensitivity of 73% (n=11) in stages I and II pancreatic cancer and 52% (n=23) in stages I and II bladder cancer. For more advanced cancer (stages III and IV), sensitivity was 84% (n=31) in pancreatic cancer and 85% (n=61) in bladder cancer. Since there is no screening paradigm or diagnostic pathway for these cancers, a specificity threshold of 95% was targeted to reduce false positive rates while ensuring ...